




Daniele	 Campa1,	 Martina	 Matarazzi1,2,	 William	 Greenhalf3,	 Maarten	 Bijlsma4,	 Kai-Uwe	 Saum5,	
Claudio	 Pasquali6,	 Hanneke	 van	 Laarhoven4,	 Andrea	 Szentesi7,8,	 Francesca	 Federici9,	 Pavel	
Vodicka10,11,12,	 Niccola	 Funel13,	 Raffaele	 Pezzilli14,	 H.B(as).	 Bueno-de-Mesquita15,16,17,18,	 Ludmila	
Vodickova10,11,12,	Daniela	Basso19,	Ofure	Obazee2,	 Thilo	Hackert20,	 Pavel	 Soucek12,	 Katarina	Cuk5,	
Jörg	 Kaiser20,	 Cosimo	 Sperti22,	 Martin	 Lovecek21,	 Gabriele	 Capurso23,	 Beatrice	 Mohelnikova-
Duchonova24,	 Kay-Tee	 Khaw25,	 Anna-Katharina	 König20,	 Juozas	 Kupcinskas26,	 Rudolf	 Kaaks27,	
Franco	 Bambi28,	 Livia	 Archibugi23,	 Andrea	Mambrini9,	 Giulia	Martina	 Cavestro29,	 Stefano	 Landi1,	
Péter	 Hegyi7,8,30,	 Jakob	 R.	 Izbicki31,	 Domenica	 Gioffreda32,	 Carlo	 Federico	 Zambon22,	 Francesca	
Tavano32,	Renata	Talar-Wojnarowska33,	 Krzysztof	 Jamroziak34,	 Timothy	 J.	 Key35,	Gianfranco	Delle	





































22. 3rd	 Surgical	 Clinic	 -	 Department	 of	 Surgery,	 Oncology	 and	 Gastroenterology	 (DiSCOG),	
University	of	Padova,	Padova,	Italy	
23. Digestive	 and	 Liver	 Disease	 Unit,	 S.	 Andrea	 Hospital,	 ‘Sapienza’	 University	 of	 Rome,	 Rome,	
Italy	





27. Division	 of	 Cancer	 Epidemiology,	 German	 Cancer	 Research	 Center	 (DKFZ),	 Heidelberg,	
Germany	
28. Blood	Transfusion	Service,	Azienda	Ospedaliero	Universitaria	Meyer,	Florence,	Italy	
29. Gastroenterology	 and	 Gastrointestinal	 Endoscopy	 Unit,	 Vita-Salute	 San	 Raffaele	 University,	
San	Raffaele	Scientific	Institute,	Milan,	Italy	
30. MTA-SZTE	Momentum	Translational	Gastroenterology	Research	Group,	Szeged,	Hungary	
31. Department	of	General,	Visceral	 and	Thoracic	 Surgery,	University	Medical	 Center	Hamburg-
Eppendorf,	Hamburg,	Germany	
	 3	




35. Cancer	 Epidemiology	 Unit	 Nuffield	 Department	 of	 Population	 Health,	 University	 of	 Oxford,	
Oxford,	United	Kingdom	
36. ARC-NET,	University	and	Hospital	Trust	of	Verona,	Verona,	Italy	




39. German	 Cancer	 Consortium	 (DKTK),	 German	 Cancer	 Research	 Center	 (DKFZ),	 Heidelberg,	
Germany	
	





Abbreviations:	 LTL:	 leucocyte	 telomere	 length;	 PDAC:	 pancreatic	 ductal	 adenocarcinoma;	 SNP:	














Telomere	 deregulation	 is	 a	 hallmark	 of	 cancer.	 Telomere	 length	 measured	 in	 lymphocytes	
(LTL)	 has	 been	 shown	 to	 be	 a	 risk	 marker	 for	 several	 cancers.	 For	 pancreatic	 ductal	
adenocarcinoma	 (PDAC)	 consensus	 is	 lacking	 whether	 risk	 is	 associated	 with	 long	 or	 short	
telomeres.	 Mendelian	 randomization	 approaches	 have	 shown	 that	 a	 score	 built	 from	 SNPs	
associated	with	LTL	could	be	used	as	a	robust	risk	marker.	We	explored	this	approach	 in	a	 large	
scale	study	within	the	PANcreatic	Disease	ReseArch	(PANDoRA)	consortium.	We	analyzed	10	SNPs	
(ZNF676-rs409627,	 TERT-rs2736100,	 CTC1-rs3027234,	 DHX35-rs6028466,	 PXK-rs6772228,	 NAF1-
rs7675998,	 ZNF208-rs8105767,	 OBFC1-rs9420907,	 ACYP2-rs11125529	 and	 TERC-rs10936599)	
alone	 and	 combined	 in	 a	 LTL	 genetic	 score	 (“teloscore”,	 which	 explains	 2.2%	 of	 the	 telomere	
variability)	 in	 relation	 to	 PDAC	 risk	 in	 2,374	 cases	 and	 4,326	 controls.	 We	 identified	 several	
associations	 with	 PDAC	 risk,	 among	 which	 the	 strongest	 were	 with	 the	 TERT-rs2736100	 SNP	
(OR=1.54;	 95%CI	 1.35-1.76;	 p=1.54x10-10)	 and	 a	 novel	 one	 with	 the	 NAF1-rs7675998	 SNP	
(OR=0.80;	95%CI	0.73-0.88;	p=1.87x10⁻⁶,	ptrend=3.27x10⁻⁷).	The	association	of	short	LTL,	measured	
by	 the	 teloscore,	with	 PDAC	 risk	 reached	 genome-wide	 significance	 (p=2.98x10-9	 for	 highest	 vs.	
lowest	quintile;	p=1.82x10-10	as	a	continuous	variable).	In	conclusion,	we	present	a	novel	genome-

















Pancreatic	 cancer	 is	 a	 relatively	 rare	 disease,	 but	 it	 currently	 ranks	 as	 the	 fourth	 cause	 of	
cancer-related	deaths	in	Europe	and	USA,	and	is	projected	to	become	the	second	in	a	few	years.1	
There	are	several	established	or	suggested	environmental	risk	factors	for	pancreatic	cancer	such	
as	 smoking,	 heavy	 alcohol	 abuse	 and	 predisposing	 conditions	 like	 family	 history	 of	 pancreatic	
cancer,	 chronic	 pancreatitis,	 obesity,	 pre-existing	 diabetes	 mellitus.2,3	 In	 the	 last	 few	 years	
genome-wide	 associations	 studies	 (GWAS)	 and	 targeted	 large	 candidate	 gene/pathway	 studies	
have	identified	several	single	nucleotide	polymorphisms	(SNPs)	associated	with	pancreatic	cancer	
susceptibility	 and	 survival.4–18	 Among	 these	 reports	 several	 point	 towards	 a	 prominent	
involvement	of	the	TERT-CLPTM1L	gene	region	in	the	disease	etiology.5,7,10,15	This	region,	situated	
on	chromosome	5p15.33,	is	pleiotropic	and	there	are	overwhelming	epidemiologic	and	molecular	
evidences	on	 the	association	of	 SNPs	belonging	 to	 it	 and	 the	 risk	of	 various	 cancer	 types.19	 The	
pleiotropy	of	the	region	is	explained	by	the	central	role	that	TERT	exerts	in	the	cell.	The	TERT	gene	
encodes	 the	 telomerase	 reverse	 transcriptase,	 and	with	 the	 telomerase	 RNA	 component	 (TERC	
gene)	forms	a	key	part	of	the	telomerase	enzymatic	complex,	which	synthesizes	telomeric	ends.20	
Even	moderate	deregulations	of	 the	 telomerase	activity	 can	 jeopardize	 telomere	homeostasis21,	
which	 in	 turn	 can	 affect	 chromosomal	 stability,	 cell	 growth	 and	 the	 correct	 segregation	 of	
chromosomes	 to	 daughter	 cells.22,23	 Interestingly,	 considerable	 evidence	 from	molecular	 cancer	
biology	 indicates	 that	 telomere	 length	 in	 healthy	 or	 non-malignant	 tissues,	 usually	 studied	 as	
lymphocyte	 telomere	 length	 (LTL),	 also	 represents	 a	 risk	 marker	 for	 a	 large	 number	 of	 tumor	
types.	Telomere	 length	 is	highly	correlated	across	tissues24,25,	 therefore	LTL	 is	considered	a	valid	
surrogate	for	the	measure	of	telomere	length	in	specific	tissues.	For	pancreatic	cancer,	five	studies	
attempted	to	 link	LTL	with	risk	of	developing	the	disease.	The	results	were	contrasting	with	two	
studies	 reporting	 an	 association	 with	 shorter	 telomere	 length	 and	 increased	 risk5,26,	 one	 study	
reporting	 longer	 telomere	 and	 increased	 risk27	 and	 two	 studies	 reporting	 a	 U-shaped	
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association.28,29	 The	 lack	 of	 consensus	 for	 pancreatic	 cancer	 reflects	 the	 conflicting	 results	
reported	 for	 other	 cancer	 types	 and	 it	 is	 at	 least	 partially	 due	 to	 the	 techniques,	 particularly	





from	 these	SNPs	as	a	 surrogate	of	 LTL	 could	be	used	as	a	 robust	 risk	marker	 for	 several	 cancer	
types.33–38	Two	studies	attempted	this	for	pancreatic	cancer,	and	found	no	association.39,40	Given	
that	pancreatic	cancer	 is	a	rare	and	very	 lethal	disease,	 it	 is	crucial	to	expand	our	knowledge	on	
risk	 factors,	 by	 conducting	 a	 Mendelian	 randomization	 analysis	 of	 telomere	 length.	 This	 is	
potentially	a	better	way	than	measuring	LTL	directly,	given	the	difficulties	in	precisely	determining	
this	phenotype.	We	explored	 this	approach	 in	a	 large	 scale	 study	within	 the	PANcreatic	Disease	






For	 this	 study	 we	 used	 2,374	 pancreatic	 cancer	 cases	 and	 4,326	 controls	 belonging	 to	 the	
PANDoRA,	EPIC	and	ESTHER	consortia.	The	PANcreatic	Disease	ReseArch	 (PANDoRA)	consortium	
has	 been	 described	 in	 detail	 elsewhere.41	 We	 collected	 cases	 and	 controls	 from	 8	 European	
countries	 (Italy,	 Germany,	 Czech	 Republic,	 Hungary,	 United	 Kingdom,	 Lithuania,	 Poland,	
Netherlands).	Cases	were	defined	by	a	confirmed	diagnosis	of	PDAC	by	histopathology.	Controls	
were	 collected	 in	 the	 same	 geographical	 regions	 as	 the	 cases,	 mostly	 in	 the	 context	 of	 the	
PANDoRA	 consortium.	 Additionally,	 a	 part	 of	 the	 German	 controls	 was	 enrolled	 in	 ESTHER,	 a	
prospective	 cohort	with	 9,953	 participants	 recruited	 during	 a	 general	 health	 check-up	 between	
July	 2000	 and	 December	 2002	 in	 Saarland	 (a	 state	 in	 South-western	 Germany).	 The	 remaining	
German	controls	and	all	of	the	British	and	Dutch	controls	were	selected	from	healthy	volunteers	
recruited	from	the	general	population	in	the	European	Prospective	Investigation	on	Cancer	(EPIC),	
an	ongoing	prospective	cohort	 study	 in	 ten	European	countries	 (http://epic.iarc.fr/).	All	 subjects	
signed	 a	 written	 consent	 form.	 Ethical	 approval	 for	 the	 PANDoRA	 study	 protocol	 (that	 in	 this	






TERT-rs2736100,	 CTC1-rs3027234,	DHX35-rs6028466,	 PXK-rs6772228,	NAF1-rs7675998,	 ZNF208-
rs8105767,	 OBFC1-rs9420907,	 ACYP2-rs11125529,	 TERC-rs10936599	 and	 ZBTB46-rs755017.	 The	
polymorphic	variant	 reported	 in	 the	original	publication	 for	 the	ZNF676	gene	was	rs412658,	but	







DNA	 was	 extracted	 from	 whole	 blood.	 Genotyping	 was	 carried	 out	 at	 the	 German	 Cancer	
Research	Center	 (DKFZ)	 in	Heidelberg,	Germany,	using	TaqMan	 (ABI,	Applied	Biosystems,	Foster	
City,	CA,	USA)	 technology.	Genotyping	was	conducted	 in	384	well	plates	and	 for	quality	control,	
duplicates	 of	 10%	 of	 the	 samples	 were	 interspersed	 throughout	 the	 plates.	 The	 order	 of	 DNA	
samples	from	case	and	control	subjects	was	randomized	on	plates	to	ensure	that	similar	numbers	






was	 computed	as	 follows:	 for	 each	SNP	 the	number	of	 alleles	 associated	with	 longer	 telomeres	
(according	 to	 the	 results	 of	 the	 literature	 reported	 in	 table	 1)	 were	 counted,	 and	 added	 up,	
resulting	 in	 the	 unweighted	 score	 for	 each	 subject.	 Since	 we	 finally	 selected	 10	 SNPs,	 the	
unweighted	score	can	assume	any	 integer	value	between	0	(shortest	telomeres)	and	20	(longest	
telomeres).	We	 then	 created	 a	weighted	 score	 for	 each	 study	 subject.	 First,	 we	 took	 from	 the	
literature	estimates	of	the	per-allele	effect	on	LTL	 in	base	pairs	for	each	SNP	(table	1).	Then,	we	
multiplied	at	each	SNP	 the	number	of	alleles	associated	with	 longer	 telomeres	by	 the	per-allele	
effect	on	 LTL	 in	base	pairs.	 Finally,	we	 summed	up	 these	quantities	 for	each	 study	 subject.	 The	
weighted	 score	 thus	 represents	 the	 estimated	 difference	 in	 telomere	 length,	measured	 in	 base	
pairs,	attributable	to	the	SNPs	under	investigation.	Only	a	subset	of	the	study	subjects	had	a	100%	
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SNP	 call	 rate	 (N=1246	 cases	 (52.5%),	 1945	 controls	 (45.0%),	 total	 3,191	 (47.6%)),	 while	 the	
remaining	 subjects	 had	 a	 call	 rate	 between	 80%	 and	 100%.	 Therefore,	 in	 order	 to	 be	 able	 to	




The	 association	 between	 the	 SNPs	 and	 PDAC	 risk	 was	 tested	 using	 unconditional	 logistic	
regression	computing	odds	ratios	 (OR)	and	95%	confidence	 intervals	 (CI).	We	used	co-dominant,	
dominant,	recessive	and	per-allele	models	of	inheritance,	calculating	also	a	trend	test	for	the	co-
dominant	 model.	 The	 threshold	 for	 statistical	 significance	 was	 therefore	 p=0.05/(10	 SNPs	 x	 4	
models)=0.00125.	
We	used	each	of	 the	 teloscores	 (weighted	and	unweighted)	 as	 continuous	 variables	 and	as	
discrete	 values,	 calculating	quintiles	based	on	 the	distribution	of	 values	of	 the	healthy	 controls.	
The	 association	 between	 the	 teloscores	 and	 PDAC	 risk	 was	 tested	 with	 logistic	 regression,	
computing	ORs	and	95%	CIs.	
For	 a	 subset	 of	 German	 controls	 from	 the	 ESTHER	 cohort	 (N=885),	 Spearman’s	 correlation	
coefficients	 were	 calculated	 between	 the	 teloscores	 and	 values	 of	 relative	 telomere	 length	
previously	obtained	with	a	real-time	quantitative	PCR	protocol.42	
All	 analyses	were	adjusted	 for	age,	 sex	and	geographic	 region	of	origin.	Additional	 analyses	
were	 performed	 including,	 as	 adjustment	 factors,	 also	 tobacco	 smoking,	 diabetes	 diagnosed	 at	
least	two	years	before	onset	of	pancreatic	cancer	and	family	history	of	pancreatic	cancer,	which	
were	 available	 for	 subsets	 of	 cases	 and	 controls	 (supplementary	 table	 2).	 We	 also	 tested	 the	
association	between	the	teloscore	and	smoking	and	diabetes	as	endpoints.	Egger	regression	was	






showing	 the	 most	 significant	 associations	 with	 risk	 of	 pancreatic	 cancer.	 RegulomeDB	
(http://regulome.stanford.edu/)43	and	HaploReg44	were	used	 to	 identify	 the	 regulatory	potential	








were	 in	 Hardy-Weinberg	 equilibrium	 when	 analyzed	 in	 controls	 with	 the	 exception	 of	 the	








When	 analyzing	 the	 effect	 of	 the	 SNPs	 on	 PDAC	 risk	 we	 observed	 several	 statistically	
significant	 associations.	 The	 strongest	 from	 a	 statistical	 point	 of	 view	 was	 between	 the	









As	 a	 first	 step	we	 checked	whether	 the	 computed	 teloscore	was	 effectively	 able	 to	 predict	
telomere	 length.	 For	 this	 purpose	 we	 used	 part	 of	 the	 controls	 for	 which	 we	 had	 previously	
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measured	 telomere	 length	 with	 a	 real-time	 quantitative	 PCR	 protocol42	 and	 we	 observed	 a	
statistically	significant	association	between	the	teloscore	and	LTL	with	a	correlation	coefficient	of	
0.122	 (p=0.0017),	 confirming	 the	 hypothesized	 association	 between	 the	 genetic	 variance	 in	
telomeric	 genes	 and	 telomere	 length.	 In	 this	 subset	of	 controls	 the	10	 SNPs	 collectively	 explain	
3.35%	 of	 the	 telomere	 length	 variation.	 We	 subsequently	 tested	 the	 association	 between	 the	
score	and	PDAC	risk.	Since	not	all	the	individuals	were	genotyped	successfully	for	all	the	selected	
SNPs,	 in	 order	 to	 increase	 our	 statistical	 power	 we	 used	 the	 average	 scores	 rather	 than	 the	
absolute	values	 (see	methods).	Considering	 the	average	 score	we	observed	a	 strong	association	
between	 genetically	 determined	 long	 telomere	 and	decreased	 risk	 of	 PDAC	when	 analyzing	 the	




cancer,	 namely	 tobacco	 smoking	 and	diabetes	diagnosed	before	onset	of	 pancreatic	 cancer.	No	
association	was	 found.	Furthermore,	we	recalculated	the	association	between	the	teloscore	and	




show	 the	 most	 significant	 associations	 with	 pancreatic	 cancer	 risk,	 and	 the	 results	 did	 not	





We	 used	 several	 bioinformatic	 tools	 to	 test	 for	 possible	 functional	 relevance	 for	 the	 four	
variants	 that	 reached	 study-wide	 significance	 (TERT-rs2736100,	 NAF1-rs7675998,	 ZNF676-
rs409627,	 ZNF208-rs8105767).	 RegulomeDB	 did	 not	 reveal	 any	 interesting	 regulatory	 potential	
associated	with	any	of	the	variants.	The	GTEx	portal	web	site,	 instead,	showed	that	all	the	SNPs,	
with	 the	exception	of	TERT-rs2736100,	are	multi-tissue	eQTLs	 (p<1.1	x10-4).	For	TERT-rs2736100	







There	 are	 overwhelming	 epidemiologic	 and	molecular	 evidences	 linking	 telomeres	with	 the	
etiology	of	 numerous	diseases.	However,	 given	 the	 capricious	nature	of	 association	 studies	 and	
the	 technical	 pitfalls	 in	 LTL	measurement,	 both	 short	 and	 long	 telomeres	 have	 been	 associated	
with	the	onset	of	multiple	cancer	types.	The	situation	is	particularly	unclear	for	pancreatic	cancer,	
with	 five	 published	 studies	 that	measured	 LTL	with	 a	 real-time	 quantitative	 PCR	 protocol.5,26–29	









We	 observed	 a	 genome-wide	 significant	 association	 (p=1.54x10-10)	 between	 the	 TERT-
rs2736100	A	allele	and	increased	PDAC	risk.	This	SNP	is	pleiotropic	and	has	been	reported	to	be	
associated,	 alongside	 telomere	 length,	 with	 several	 cancer	 types.	 TERT-rs2736100	 has	 been	
reported	by	others5	and	by	ourselves7	 to	be	associated	with	PDAC	risk,	but	 this	 is	 the	 first	 time	
that	 the	association	reaches	a	genome-wide	 level	of	significance.	This	SNP	 is	 in	very	 low	 linkage	
disequilibrium	 with	 the	 other	 SNPs	 in	 this	 region	 that	 were	 reported	 to	 be	 associated	 with	





The	 association	 between	 NAF1-rs7675998	 SNP	 and	 decreased	 risk	 of	 PDAC	 is	 novel.	 The	
association	 is	 close	 to	 a	 genome-wide	 significance	 level	 (ptrend=3.27x10⁻⁷).	 The	 NAF1	 (nuclear	
assembly	factor	1)	gene product	is	part	of	a	complex	involved	in	the	assembly	of	telomerase46	and	




has	 also	 two	eQTLs	 affecting	NAF1	 expression.	However,	 although	 these	 associations	 are	highly	
significant,	 they	 have	 not	 been	 observed	 in	 the	 pancreatic	 tissue.	 We	 observed	 two	 other	
potentially	interesting	associations	between	ZNF676-rs409627,	ZNF208-rs8105767	and	PDAC	risk.	
The	 role	 of	 these	 two	 genes	 in	 telomere	 maintenance	 has	 not	 been	 established	 yet	 although	
several	 hypotheses	 point	 to	 a	 possible	 involvement	 in	 stabilizing	 DNA	 or	 proteins	 that	 bind	 to	
DNA.47	According	to	GTEx,	rs409627	can	modify	ZNF676	expression	in	the	pancreatic	tissue	while	
rs8105767	can	modify	the	expression	of	ZNF208	in	various	tissues	but	not	in	pancreatic	cancer.	For	
both	 SNPs	 the	 allele	 associated	 with	 an	 increase	 in	 risk	 is	 the	 major	 allele,	 while	 the	 allele	
associated	with	 telomere	 shortening	 is	 the	minor	 one,	 indicating	 that	 possibly	 their	 association	
with	PDAC	risk	is	independent	from	telomere	length.	
The	 most	 important	 novel	 finding	 of	 this	 study	 is	 the	 statistically	 significant	 association	
between	genetically	determined	short	LTL	(assessed	through	the	teloscore)	and	increased	risk	of	
PDAC.	 The	 association	 reached	 genome-wide	 significance	 both	 considering	 the	 variable	 as	
categorical	(p=2.98x10-9	for	highest	vs.	lowest	quintile)	or	as	continuous	(p=1.82x10-10)	and	do	not	
support	a	U-shaped	association.	 It	 should	also	be	noted	as	a	proof	of	principle	 that	we	 found	a	
weak	 but	 significant	 correlation	 between	 the	 teloscore	 and	 LTL	 measured	 by	 an	 established	
method	 (real-time	quantitative	PCR)	 in	almost	900	controls	belonging	 to	our	dataset.	 In	 the	 last	
couple	 of	 years	 the	 approach	 of	 using	 SNPs	 related	 to	 telomere	 shortening	 as	 an	 instrumental	
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mean	to	 infer	 the	effect	of	 telomeres	on	cancer	etiology	has	been	successfully	used	 in	different	
tumor	 types	 such	 as	 B-cell	 lymphoma35,	 adult	 glioma36,	 breast	 cancer34	 and	 squamous	 cell	
carcinoma	 of	 the	 head	 and	 neck.48	 The	 use	 of	 genetic	 markers	 decreases	 the	 risk	 for	 reverse	
causation	 bias	 and	 therefore	 the	 differences	 in	 the	 studies	 (some	 finding	 association	 between	
cancer	risk	and	longer	telomeres,	some	with	shorter	telomeres)	may	reflect	tissue-specific	effects	
and	 activity	 of	 TL	 or	 a	 specific	 regulation	 of	 the	 genes	 involved	 in	 telomere	 regulation.	 It	 is	







that	 the	 results	 reported	 by	Haycock	 et	 al,	 based	 on	 the	 PanScan	GWAS	 (5105	 cases	 and	 8739	
controls),	 show	a	non-significant	 associations	between	 shorter	 telomeres	 and	pancreatic	 cancer	
risk	 (OR=0.86;	 95%CI	 0.56-1.32;	 p=0.50	 for	 PanSan	 and	OR=0.74,	 95%CI	 0.53-1.02,	 p=0.0657	 for	
PanC4),	which	are	compatible	with	our	results.40	The	results	of	the	other	study	do	not	show	any	












in	a	group	of	 individuals	for	which	telomere	 length	was	measured	by	RT-PCR	homogeneously,	 in	
the	 same	 laboratory,	 in	 samples	 collected	 from	 the	 same	 center	 (the	 controls	 belonging	 to	 the	
ESTHER	cohort	n=885)	and	using	exactly	the	same	procedure	for	sample	handling	and	storing.	A	
possible	 drawback	 is	 that	 we	 tested	 the	 teloscore	 on	 DNA	 collected	 from	 leukocytes	 and	 it	 is	
therefore	difficult	to	generalize	its	ability	to	be	used	as	a	proxy	for	other	tissues.	However,	there	is	
a	 growing	 literature	 suggesting	 that	 telomere	 shortening	 is	 generally	 consistent	 in	 different	
tissues50	and	that	the	variation	among	different	tissues	belonging	to	the	same	individual	is	lower	
that	 the	 variability	 between	 different	 individuals.49,51	 Additionally,	 an	 analysis	 with	 Egger	
regression	 did	 not	 yield	 a	 significant	 result,	 and	 pointed	 to	 high	 heterogeneity	 among	 SNPs,	
suggesting	a	possible	pleiotropic	effect	of	our	SNPs.	
In	 conclusion,	 here	we	present	 a	 novel	 genome-wide	 candidate	 for	 PDAC	 (TERT-rs2736100)	














Sports	 (VWS),	 Netherlands	 Cancer	 Registry	 (NKR),	 LK	 Research	 Funds,	 Dutch	 Prevention	 Funds,	





Author	 contributions:	 D.C.	 and	 F.C.	 conceived	 the	 study.	 M.M.	 performed	 experimental	 work.	
D.C.,	 F.C.	 and	M.M.	 performed	 data	 analysis.	 All	 other	 authors	 contributed	 to	 the	 collection	 of	











4.	 Amundadottir	 L,	 Kraft	 P,	 Stolzenberg-Solomon	 RZ,	 et	 al.	 Genome-wide	 association	 study	 identifies	
variants	in	the	ABO	locus	associated	with	susceptibility	to	pancreatic	cancer.	Nat	Genet	2009;41:986–
990.	
5.	 Bao	Y,	Prescott	 J,	Yuan	C,	et	al.	Leucocyte	telomere	 length,	genetic	variants	at	 the	TERT	gene	region	
and	risk	of	pancreatic	cancer.	Gut	2016;66:1116–1122.	
6.	 Campa	 D,	 Pastore	M,	 Gentiluomo	M,	 et	 al.	 Functional	 single	 nucleotide	 polymorphisms	 within	 the	

















14.	 Willis	 JA,	 Olson	 SH,	 Orlow	 I,	 et	 al.	 A	 replication	 study	 and	 genome-wide	 scan	 of	 single-nucleotide	




16.	 Wu	 C,	 Kraft	 P,	 Stolzenberg-Solomon	 R,	 et	 al.	 Genome-wide	 association	 study	 of	 survival	 in	 patients	
with	pancreatic	adenocarcinoma.	Gut	2012;63:152–160.	
17.	 Wu	 C,	 Miao	 X,	 Huang	 L,	 et	 al.	 Genome-wide	 association	 study	 identifies	 five	 loci	 associated	 with	
susceptibility	to	pancreatic	cancer	in	Chinese	populations.	Nat	Genet	2011;44:62–66.	
18.	 Zhang	M,	Wang	 Z,	 Obazee	O,	 et	 al.	 Three	 new	 pancreatic	 cancer	 susceptibility	 signals	 identified	 on	
chromosomes	1q32.1,	5p15.33	and	8q24.21.	Oncotarget	2016;7:66328–66343.	
19.	 Mocellin	 S,	 Verdi	 D,	 Pooley	 KA,	 et	 al.	 Telomerase	 reverse	 transcriptase	 locus	 polymorphisms	 and	
cancer	risk:	a	field	synopsis	and	meta-analysis.	J	Natl	Cancer	Inst	2012;104:840–854.	
20.	 Blackburn	EH.	Switching	and	signaling	at	the	telomere.	Cell	2001;106:661–673.	






24.	 Kimura	 M,	 Gazitt	 Y,	 Cao	 X,	 et	 al.	 Synchrony	 of	 telomere	 length	 among	 hematopoietic	 cells.	 Exp	
Hematol	2010;38:854–859.	




in	 the	alpha-tocopherol	 beta-carotene	 cancer	 (ATBC)	prevention	 study.	 Int	 J	 Cancer	 2013;133:2672–
2680.	
















35.	 Machiela	MJ,	 Lan	Q,	Slager	SL,	et	al.	Genetically	predicted	 longer	 telomere	 length	 is	associated	with	
increased	risk	of	B-cell	lymphoma	subtypes.	Hum	Mol	Genet	2016;25:1663–1676.	
36.	 Walsh	 KM,	 Codd	 V,	 Rice	 T,	 et	 al.	 Longer	 genotypically-estimated	 leukocyte	 telomere	 length	 is	
associated	with	increased	adult	glioma	risk.	Oncotarget	2015;6:42468–42477.	
37.	 Walsh	 KM,	 Codd	V,	 Smirnov	 IV,	 et	 al.	 Variants	 near	 TERT	 and	 TERC	 influencing	 telomere	 length	 are	
associated	with	high-grade	glioma	risk.	Nat	Genet	2014;46:731–735.	







41.	 Campa	 D,	 Rizzato	 C,	 Capurso	 G,	 et	 al.	 Genetic	 susceptibility	 to	 pancreatic	 cancer	 and	 its	 functional	
characterisation:	 the	PANcreatic	Disease	ReseArch	 (PANDoRA)	consortium.	Dig	Liver	Dis	2013;45:95–
99.	
42.	 Campa	 D,	Martino	 A,	 Varkonyi	 J,	 et	 al.	 Risk	 of	multiple	myeloma	 is	 associated	with	 polymorphisms	
within	telomerase	genes	and	telomere	length.	Int	J	Cancer	2015;136:E351–E358.	































rs409627c	 19	 22,176,638	 ZNF676	 G/C	 C	 0.086	 0.010	 0.484	 103.2	
rs2736100	 5	 1,286,401	 TERT	 C/A	 C	 0.085	 0.013	 0.310	 102.0	
rs3027234	 17	 8,232,774	 CTC1	 C/T	 C	 0.103	 0.012	 0.292	 123.6	
rs6028466	 20	 39,500,359	 DHX35	 G/A	 A	 0.058	 0.013	 0.041	 69.6	
rs6772228	 3	 58,390,292	 PXK	 T/A	 T	 0.041	 0.014	 0.200	 49.2	
rs7675998	 4	 163,086,668	 NAF1	 G/A	 G	 0.048	 0.012	 0.190	 57.6	
rs8105767	 19	 22,032,639	 ZNF208	 A/G	 G	 0.064	 0.011	 0.090	 76.8	
rs9420907	 10	 103,916,707	 OBFC1	 A/C	 C	 0.142	 0.014	 0.171	 170.4	
rs11125529	 2	 54,248,729	 ACYP2	 C/A	 A	 0.065	 0.012	 0.080	 78.0	
rs10936599	 3	 169,774,313	 TERC	 C/T	 C	 0.100	 0.011	 0.319	 120.0	
	
aData	from	refs.	52	and	40.	


































MM	 Mm	 mm	 MM	vs.	Mm	 MM	vs.	mm	 Ptrend	 MM	vs.	Mm+mm	 Mm+MM	vs.	mm	 M	vs.	m	
OR	(95%CI)b	 Phet	 OR	(95%CI)	 Phom	 OR	(95%CI)	 Pdom	 OR	(95%CI)	 Prec	 OR	(95%CI)b	 P	
ZNF676	 rs409627c	 G/C	 710/1633	 803/1864	 230/616	 1.04	(0.91-1.19)	 0.563	 0.78	(0.64-0.95)	 0.011	 0.1552	 0.97	(0.86-1.10)	 0.656	 0.76	(0.64-0.91)	 0.003	 0.92	(0.84-1.01)	 0.071	
TERT	 rs2736100	 C/A	 598/1226	 983/1979	 581/818	 1.02	(0.89-1.17)	 0.778	 1.56	(1.34-1.83)	 2.60x10⁻⁸	 1.05x10⁻⁶	 1.17	(1.03-1.33)	 0.013	 1.54	(1.35-1.76)	 1.54x10⁻10	 1.24	(1.15-1.34)	 1.08x10-7	
CTC1	 rs3027234	 C/T	 1328/2521	 869/1528	 143/240	 1.09	(0.97-1.22)	 0.154	 1.09	(0.86-1.37)	 0.490	 0.1017	 1.09	(0.97-1.21)	 0.137	 1.05	(0.84-1.32)	 0.673	 1.06	(0.97-1.16)	 0.17	
DHX35	 rs6028466	 G/A	 2085/3687	 215/448	 18/24	 0.86	(0.72-1.04)	 0.118	 1.13	(0.59-2.16)	 0.716	 0.2118	 0.88	(0.73-1.05)	 0.156	 1.14	(0.60-2.19)	 0.684	 0.91	(0.77-1.07)	 0.233	
PXK	 rs6772228	 T/A	 2141/3738	 149/224	 6/12	 1.15	(0.91-1.46)	 0.242	 1.04	(0.37-2.95)	 0.935	 0.2545	 1.15	(0.91-1.45)	 0.247	 1.04	(0.37-2.93)	 0.948	 1.13	(0.91-1.40)	 0.273	
NAF1	 rs7675998	 G/A	 1451/2444	 753/1548	 102/284	 0.81	(0.72-0.92)	 0.001	 0.61	(0.48-0.79)	 1.18x10⁻⁴	 3.27x10⁻⁷	 0.78	(0.70-0.88)	 1.81x10⁻⁵	 0.66	(0.51-0.84)	 0.001	 0.80	(0.73-0.88)	 1.87x10-6	
ZNF208	 rs8105767	 A/G	 1197/1701	 912/1391	 200/343	 0.98	(0.85-1.12)	 0.719	 0.68	(0.53-0.87)	 0.002	 0.0391	 0.92	(0.80-1.04)	 0.184	 0.69	(0.54-0.87)	 0.002	 0.88	(0.80-0.98)	 0.018	
OBFC1	 rs9420907	 A/C	 1639/2992	 640/1174	 68/115	 0.99	(0.88-1.12)	 0.883	 1.16	(0.82-1.62)	 0.403	 0.8429	 1.00	(0.89-1.13)	 0.943	 1.16	(0.83-1.62)	 0.392	 1.02	(0.92-1.13)	 0.746	
ACYP2	 rs11125529	 C/A	 1732/2441	 474/719	 39/74	 1.04	(0.90-1.20)	 0.598	 0.85	(0.55-1.30)	 0.441	 0.0941	 1.02	(0.89-1.178)	 0.767	 0.84	(0.55-1.28)	 0.415	 1.00	(0.88-1.13)	 0.987	









Scorea	 Controls	 Cases	 OR	 95%	CI	 Pvalue	
Quintile	1	(0-47.22)	 865	 580	 Ref.	 -	 -	
Quintile	2	(47.23-55.30)	 865	 555	 0.99	 (0.85-1.17)	 0.95	
Quintile	3	(55.31-61.80)	 866	 426	 0.74	 (0.63-0.88)	 5.30x10-4	
Quintile	4	(61.81-70.56)	 864	 469	 0.80	 (0.67-0.94)	 7.48x10-3	
Quintile	5	(70.57-112.05)	 866	 344	 0.59	 (0.49-0.70)	 2.98x10-9	
























































































































































































































Effect	alleleh	 C	 C	 C	 A	 T	 G	 G	 C	 A	 C	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Other	allele	 G	 A	 T	 G	 A	 A	 A	 A	 C	 T	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Effect	allele	frequency	 0.35	 0.52	 0.83	 0.17	 0.87	 0.80	 0.25	 0.14	 0.16	 0.76	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Betai	 0.086	 0.085	 0.103	 0.058	 0.041	 0.048	 0.064	 0.142	 0.065	 0.100	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Base	pairsj	 103.2	 102.0	 123.6	 69.6	 49.2	 57.6	 76.8	 170.4	 78.0	 120.0	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Subject1	 G/G	 C/A	 C/C	 G/G	 T/T	 A/A	 A/A	 A/A	 C/C	 C/T	 10	 0	 1	 2	 0	 2	 0	 0	 0	 0	 1	 6	 0.60	 0	 102.0	 247.2	 0	 98.4	 0	 0	 0	 0	 120.0	 567.6	 56.76	
Subject2	 G/G	 C/A	 C/C	 G/G	 T/T	 G/G	 A/A	 A/A	 C/C	 C/C	 10	 0	 1	 2	 0	 2	 2	 0	 0	 0	 2	 9	 0.90	 0	 102.0	 247.2	 0	 98.4	 115.2	 0	 0	 0	 240.0	 802.8	 80.28	
Subject3	 C/C	 C/A	 C/T	 G/G	 T/T	 G/A	 G/G	 A/A	 C/C	 C/C	 10	 2	 1	 1	 0	 2	 1	 2	 0	 0	 2	 11	 1.10	 206.4	 102.0	 123.6	 0	 98.4	 57.6	 153.6	 0	 0	 240.0	 981.6	 98.16	
Subject4	 G/G	 C/C	 C/C	 G/G	 T/T	 G/G	 A/G	 A/A	 C/C	 C/C	 10	 0	 2	 2	 0	 2	 2	 1	 0	 0	 2	 11	 1.10	 0	 204.0	 247.2	 0	 98.4	 115.2	 76.8	 0	 0	 240.0	 981.6	 98.16	
Subject5	 G/G	 C/A	 C/C	 G/G	 T/T	 A/A	 A/A	 A/A	 C/C	 C/T	 10	 0	 1	 2	 0	 2	 0	 0	 0	 0	 1	 6	 0.60	 0	 102.0	 247.2	 0	 98.4	 0	 0	 0	 0	 120.0	 567.6	 56.76	
Subject6	 C/C	 C/C	 C/T	 G/G	 T/T	 G/G	 G/G	 C/C	 C/A	 C/T	 10	 2	 2	 1	 0	 2	 2	 2	 2	 1	 1	 15	 1.50	 206.4	 204.0	 123.6	 0	 98.4	 115.2	 153.6	 340.8	 78.0	 120.0	 1440.0	 144	
Subject7	 G/C	 C/A	 C/C	 G/G	 T/T	 G/A	 A/A	 A/A	 C/C	 C/C	 10	 1	 1	 2	 0	 2	 1	 0	 0	 0	 2	 9	 0.90	 103.2	 102.0	 247.2	 0	 98.4	 57.6	 0	 0	 0	 240.0	 848.4	 84.84	
Subject8	 G/G	 C/A	 C/C	 G/G	 T/T	 G/G	 A/A	 A/C	 C/C	 C/C	 10	 0	 1	 2	 0	 2	 2	 0	 1	 0	 2	 10	 1.00	 0	 102.0	 247.2	 0	 98.4	 115.2	 0	 170.4	 0	 240.0	 973.2	 97.32	
Subject9	 -	 C/A	 C/T	 G/G	 T/T	 G/G	 A/G	 A/C	 C/C	 C/T	 9	 -	 1	 1	 0	 2	 2	 1	 1	 0	 1	 9	 1.00	 	 102.0	 123.6	 0	 98.4	 115.2	 76.8	 170.4	 0	 120.0	 806.4	 89.6	



























Study	 Measurement	type	 Cases/controls	 Study	type	 Effect	observed	 Ethnicity	 Reference	in	
the	manuscript	
Skinner	et.	al	2012	 Real-time	PCR	 499/963	 Retrospective	 Short	telomeres	increase	risk	 European-Americans	 27	
Lynch	et.al,	2013	 Real-time	PCR	 193/660	 Prospective	cohort	 Long	telomeres	increase	risk	 Finnish	 26	
Campa	et	al,	2014	 Real-time	PCR	 331/331	 Prospective	cohort	 U-shaped	 Europeans	 28	
Zhang	et.	Al,	2016	 Real-time	PCR	 900/900	 Prospective	cohort	 U-shaped	 Chinese	 29	
Bao	et	al.	2016	 Real-time	PCR	 386/896		 Prospective	cohort	 Short	telomeres	increase	risk	 European-Americans	 5	
	
	
